• Exelixis reported earnings per share (EPS) of $0.48, slightly below the estimated $0.51, but generated revenue of approximately $566.8 million, surpassing the estimated $563.2 million.
• The company's fourth-quarter 2024 results showed a significant 18.2% revenue increase compared to the previous year.
• Exelixis has a price-to-earnings (P/E) ratio of approximately 20.07, indicating the market's valuation of its earnings, and maintains a low debt-to-equity ratio of 0.085, highlighting its strong financial position.

Exelixis, Inc. (NASDAQ: EXEL) is a biopharmaceutical company focused on developing oncology treatments. It is known for its cabozantinib franchise, marketed as CABOMETYX and COMETRIQ. The company competes in a challenging oncology market, facing competition and regulatory hurdles as it expands its cancer therapies.

On February 11, 2025, Exelixis reported earnings per share (EPS) of $0.48, slightly below the estimated $0.51. Despite this, the company generated revenue of approximately $566.8 million, surpassing the estimated $563.2 million. This revenue growth reflects the company's strong performance in the oncology market.

Exelixis's fourth-quarter 2024 results showed a significant 18.2% revenue increase compared to the previous year. Michael M. Morrissey, Ph.D., President and CEO, expressed confidence in Exelixis's positioning for success in 2025. The company is preparing for potential U.S. regulatory approval of CABOMETYX for advanced neuroendocrine tumors.

Exelixis has a price-to-earnings (P/E) ratio of approximately 20.07, indicating the market's valuation of its earnings. The company's price-to-sales ratio is about 4.50, and its enterprise value to sales ratio is roughly 4.47. With a debt-to-equity ratio of 0.085, Exelixis maintains a low level of debt compared to its equity, highlighting its strong financial position.